Mesenchymal stem cells promote ovarian reconstruction in mice

• Published in: Stem cell research & therapy Vol. 15; no. 1; p. 115
• Main Authors: Li, Jiazhao, Fan, Haonan, Liu, Wei, Zhang, Jing, Xiao, Yue, Peng, Yue, Yang, Weijie, Liu, Wenwen, He, Yuanlin, Qin, Lianju, Ma, Xiang, Li, Jing
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.04.2024; BioMed Central; BMC
• Subjects: Analysis; Animals; Artificial ovary; Cancer; Chemotherapy; Female; Fertility preservation; Fluorescence; Health aspects; Immunohistochemistry; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - metabolism; Mice; Oocytes - cytology; Oocytes - metabolism; Ovarian Follicle - cytology; Ovarian Follicle - metabolism; Ovary - cytology; Stem cells; Women; Artificial ovary; Fertility preservation; Mesenchymal stem cells
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-024-03718-z

Studies have shown that chemotherapy and radiotherapy can cause premature ovarian failure and loss of fertility in female cancer patients. Ovarian cortex cryopreservation is a good choice to preserve female fertility before cancer treatment. Following the remission of the disease, the thawed ovarian tissue can be transplanted back and restore fertility of the patient. However, there is a risk to reintroduce cancer cells in the body and leads to the recurrence of cancer. Given the low success rate of current in vitro culture techniques for obtaining mature oocytes from primordial follicles, an artificial ovary with primordial follicles may be a good way to solve this problem. In the study, we established an artificial ovary model based on the participation of mesenchymal stem cells (MSCs) to evaluate the effect of MSCs on follicular development and oocyte maturation. P2.5 mouse ovaries were digested into single cell suspensions and mixed with bone marrow derived mesenchymal stem cells (BM-MSCs) at a 1:1 ratio. The reconstituted ovarian model was then generated by using phytohemagglutinin. The phenotype and mechanism studies were explored by follicle counting, immunohistochemistry, immunofluorescence, in vitro maturation (IVM), in vitro fertilization (IVF), real-time quantitative polymerase chain reaction (RT-PCR), and Terminal-deoxynucleotidyl transferase mediated nick end labeling(TUNEL) assay. Our study found that the addition of BM-MSCs to the reconstituted ovary can enhance the survival of oocytes and promote the growth and development of follicles. After transplanting the reconstituted ovaries under kidney capsules of the recipient mice, we observed normal folliculogenesis and oocyte maturation. Interestingly, we found that BM-MSCs did not contribute to the formation of follicles in ovarian aggregation, nor did they undergo proliferation during follicle growth. Instead, the cells were found to be located around growing follicles in the reconstituted ovary. When theca cells were labeled with CYP17a1, we found some overlapped staining with green fluorescent protein(GFP)-labeled BM-MSCs. The results suggest that BM-MSCs may participate in directing the differentiation of theca layer in the reconstituted ovary. The presence of BM-MSCs in the artificial ovary was found to promote the survival of ovarian cells, as well as facilitate follicle formation and development. Since the cells didn't proliferate in the reconstituted ovary, this discovery suggests a potential new and safe method for the application of MSCs in clinical fertility preservation by enhancing the success rate of cryo-thawed ovarian tissues after transplantation.